Drug Profile
AGSCT 101
Alternative Names: AG SCT101; AGSCTLatest Information Update: 22 Mar 2018
Price :
$50
*
At a glance
- Originator Ahn-Gook Pharmaceutical
- Class Antihypertensives
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Essential hypertension
Most Recent Events
- 22 Mar 2018 Launched for Essential hypertension in South Korea (PO) before March 2018 (Ahn-Gook Pharmaceuticals pipeline, March 2018)
- 21 Mar 2018 Registered for Essential hypertension in South Korea (PO) before March 2018 (Ahn-Gook Pharmaceuticals pipeline, March 2018)
- 16 Mar 2018 Preregistration for Essential hypertension in South Korea (PO) before March 2018 (Ahn-Gook Pharmaceuticals pipeline, March 2018)